

B3
Sub C
6. (Twice Amended) A method of claim 4, wherein the angiotensin converting enzyme inhibitor is alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril, or zofenoprilat.

B3 Sub C
19. (New) A method as claimed in claim 4, wherein the angiotensin converting enzyme inhibitor is ramipril.

Remarks

I. Status of the claims

Claims 4, 6-7 and 18-19 are pending in this application. Applicants have incorporated the subject matter of claim 5 into claim 4. Applicants have also canceled claims 8-17, but reserve the right to pursue any canceled subject matter in a separate patent application. The amendments to claims 4 and 6 are shown in the first Appendix. For the Examiner's convenience, applicants attach a clean copy of all claims now pending, including new claim 19, in the second Appendix.

II. Rejections under 35 U.S.C. § 102

The Examiner rejected claims 10-13 and 16-17 under 35 U.S.C. § 102(b) as anticipated by WO 96/24373 to Maclaughlan et al. ("Maclaughlan"). The Examiner also rejected claims 14 and 15 as anticipated by an FDA Orange Book Active Ingredient Detail Record Search.